Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Acitretin

FDA-approved product (capsule, oral), marketed as Acitretin, Soriatane.

Registered studies
42
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Acitretin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Psoriasis
  • Psoriasis vulgaris

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Retinoids for treatment of psoriasis
FDA pharmacologic class
Retinoid FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA34.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli20.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

42registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Acitretin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Acitretin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma

    NCT02050321 · start 2013-12

    Registered record
    Registry ID
    NCT02050321
    Conditions
    Malignant Melanoma
    Interventions
    Acitretin; Vemurafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2013-12
    Completion
    2015-07
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Melanoma
    InterventionAcitretin; Vemurafenib
    PhasePhase 2
    Registry statusTerminated

  • Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation

    NCT02330380 · start 2013-04

    Registered record
    Registry ID
    NCT02330380
    Conditions
    Psoriasis; Inflammation
    Interventions
    Methotrexate; Ustekinumab; Etanercept; Adalimumab; Acitretin; UVB Excimer Laser; Narrowband UVB
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2013-04
    Completion
    2016-12
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis; Inflammation
    InterventionMethotrexate; Ustekinumab; Etanercept; Adalimumab +3 more
    PhaseNot recorded
    Registry statusCompleted

  • Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis

    NCT01812954 · start 2013-03

    Registered record
    Registry ID
    NCT01812954
    Conditions
    Psoriasis
    Interventions
    Methotrexate; Cyclosporins; fumaric acid; Acitretin; Infliximab; etanercept; Adalimumab; Ustekinumab
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2013-03
    Completion
    2014-06
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionMethotrexate; Cyclosporins; fumaric acid; Acitretin +4 more
    PhaseNot recorded
    Registry statusCompleted

  • Efficacy and Safety Study of Total Glucosides of Paeony Combined With Acitretin to Treat Psoriasis

    NCT02191020 · start 2013-02

    Registered record
    Registry ID
    NCT02191020
    Conditions
    Psoriasis
    Interventions
    Total glucosides of paeony & Acitretin Capsules; Acitretin Capsules
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-02
    Completion
    2013-10
    Enrolment
    108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionTotal glucosides of paeony & Acitretin Capsules; Acitretin Capsules
    PhaseNot applicable
    Registry statusCompleted

  • A Study to Determine the Efficacy of Taclonex Topical Suspension as a Supplement to Non-biologic Systemic Therapy

    NCT01761019 · start 2013-01

    Registered record
    Registry ID
    NCT01761019
    Conditions
    Psoriasis
    Interventions
    Taclonex Topical Suspension
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-01
    Completion
    2014-09
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionTaclonex Topical Suspension
    PhasePhase 4
    Registry statusCompleted

  • Pilot Study on the Use of Acitretin for the Treatment of Severe Chronic Hand Dermatitis

    NCT01545284 · start 2012-03

    Registered record
    Registry ID
    NCT01545284
    Conditions
    Chronic Hand Dermatitis
    Interventions
    Acitretin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2012-03
    Completion
    2014-01
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hand Dermatitis
    InterventionAcitretin
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Psoriasis Vulgaris - CHINA201002016-2

    NCT01443338 · start 2011-09

    Registered record
    Registry ID
    NCT01443338
    Conditions
    Psoriasis Vulgaris
    Interventions
    Triptergium Wilfordii; Acitretin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2011-09
    Completion
    Not recorded
    Enrolment
    720

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis Vulgaris
    InterventionTriptergium Wilfordii; Acitretin
    PhasePhase 4
    Registry statusUnknown

  • Swiss Dermatology Network of Targeted Therapies (SDNTT)

    NCT01706692 · start 2011-02

    Registered record
    Registry ID
    NCT01706692
    Conditions
    Psoriasis
    Interventions
    Adalimumab; Etanercept; Infliximab; Ustekinumab; Cyclosporine A; Fumaric acids; Methotrexate; Other anti-psoriatic systemic treatments
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2011-02
    Completion
    2032-03-15
    Enrolment
    1,121

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionAdalimumab; Etanercept; Infliximab; Ustekinumab +4 more
    PhaseNot recorded
    Registry statusRecruiting

  • Study of Acitretin to Treat Skin Rash Caused by Erlotinib (a Chemotherapy Drug)

    NCT01299220 · start 2010-11

    Registered record
    Registry ID
    NCT01299220
    Conditions
    Skin Rash
    Interventions
    Acitretin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2010-11
    Completion
    2011-09
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin Rash
    InterventionAcitretin
    PhasePhase 4
    Registry statusWithdrawn

  • Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects?

    NCT01228409 · start 2010-10

    Registered record
    Registry ID
    NCT01228409
    Conditions
    Psoriasis
    Interventions
    Acitretin 17.5 mg/day
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2010-10
    Completion
    Not recorded
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionAcitretin 17.5 mg/day
    PhasePhase 4
    Registry statusUnknown

  • Regulatory T-cells in Psoriasis Patients as Targets for Therapy

    NCT01233583 · start 2010-06

    Registered record
    Registry ID
    NCT01233583
    Conditions
    Psoriasis
    Interventions
    Dovobet, neotigason, etanercept, adalimumab. infliximab
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-06
    Completion
    2013-09
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionDovobet, neotigason, etanercept, adalimumab. infliximab
    PhaseNot recorded
    Registry statusCompleted

  • Alzheimer's Disease Acitretin Medication

    NCT01078168 · start 2010-03

    Registered record
    Registry ID
    NCT01078168
    Conditions
    Alzheimer Disease
    Interventions
    Acitretin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-03
    Completion
    2013-05
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease
    InterventionAcitretin; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis

    NCT01094717 · start 2010-01

    Registered record
    Registry ID
    NCT01094717
    Conditions
    Psoriasis
    Interventions
    Acitretin 25Mg Oral Capsule; Excimer laser; Tazarotene 0.1% Gel,Top; Sham excimer laser
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2010-01
    Completion
    2011-10
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionAcitretin 25Mg Oral Capsule; Excimer laser; Tazarotene 0.1% Gel,Top; Sham excimer laser
    PhaseNot applicable
    Registry statusTerminated

  • Trial of an Injectable Biologic and U0279 as Combination Therapy for Severe Plaque-Type Psoriasis

    NCT00832364 · start 2009-10

    Registered record
    Registry ID
    NCT00832364
    Conditions
    Plaque Psoriasis
    Interventions
    Acitretin (also called U0279); Placebo; Etanercept
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2009-10
    Completion
    2010-04
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlaque Psoriasis
    InterventionAcitretin (also called U0279); Placebo; Etanercept
    PhasePhase 4
    Registry statusWithdrawn

  • Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe Psoriasis

    NCT00936065 · start 2009-07

    Registered record
    Registry ID
    NCT00936065
    Conditions
    Moderate to Severe Psoriasis
    Interventions
    Etanercept; Etanercept + Acitretin; Acitretin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-07
    Completion
    2011-04
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionModerate to Severe Psoriasis
    InterventionEtanercept; Etanercept + Acitretin; Acitretin
    PhasePhase 4
    Registry statusCompleted